The benefits of Endo International Plc's long-acting opioid painkiller no longer outweigh its risks, an independent panel to the U.S. Food and Drug Administration (FDA) concluded on Tuesday.
The advisory committee meeting was called to address the high abuse rate of Endo's Opana ER and other oxymorphone formulations, as the health regulator looks to stem the tide of opioid abuse, overdose and addiction.
